CL2023001012A1 - Métodos para el tratamiento del cáncer - Google Patents
Métodos para el tratamiento del cáncerInfo
- Publication number
- CL2023001012A1 CL2023001012A1 CL2023001012A CL2023001012A CL2023001012A1 CL 2023001012 A1 CL2023001012 A1 CL 2023001012A1 CL 2023001012 A CL2023001012 A CL 2023001012A CL 2023001012 A CL2023001012 A CL 2023001012A CL 2023001012 A1 CL2023001012 A1 CL 2023001012A1
- Authority
- CL
- Chile
- Prior art keywords
- egfr
- her2
- cancer
- treatment
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089965P | 2020-10-09 | 2020-10-09 | |
| US202163151468P | 2021-02-19 | 2021-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001012A1 true CL2023001012A1 (es) | 2023-12-22 |
Family
ID=78516928
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001012A CL2023001012A1 (es) | 2020-10-09 | 2023-04-06 | Métodos para el tratamiento del cáncer |
| CL2025004052A CL2025004052A1 (es) | 2020-10-09 | 2025-12-22 | Derivados pirazolo[3,2-c]piridinona, inhibidores egfr y/o her2; composición; uso en cáncer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2025004052A CL2025004052A1 (es) | 2020-10-09 | 2025-12-22 | Derivados pirazolo[3,2-c]piridinona, inhibidores egfr y/o her2; composición; uso en cáncer |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20240101576A1 (https=) |
| EP (1) | EP4225445A2 (https=) |
| JP (1) | JP2023548657A (https=) |
| KR (1) | KR20230107419A (https=) |
| AU (1) | AU2021358596A1 (https=) |
| BR (1) | BR112023006531A2 (https=) |
| CA (1) | CA3198202A1 (https=) |
| CL (2) | CL2023001012A1 (https=) |
| IL (1) | IL301929A (https=) |
| MX (1) | MX2023004085A (https=) |
| PH (1) | PH12023500010A1 (https=) |
| TW (1) | TW202227063A (https=) |
| WO (1) | WO2022076831A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| EP4323356A1 (en) | 2021-04-13 | 2024-02-21 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| IL321504A (en) * | 2022-12-23 | 2025-08-01 | Tay Therapeutics Ltd | Selective beta inhibitors and their uses |
| CN115819418B (zh) * | 2023-02-14 | 2023-04-28 | 山东绿叶制药有限公司 | Plk1激酶抑制剂及其制备方法和应用 |
| CN121909190A (zh) * | 2023-06-08 | 2026-04-21 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4H-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| CN121712773A (zh) | 2023-06-08 | 2026-03-20 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
| CN119528906A (zh) * | 2023-08-30 | 2025-02-28 | 中国科学院上海药物研究所 | 氮杂螺环类化合物及其制备方法、药物组合物和应用 |
| EP4534085A1 (en) * | 2023-10-03 | 2025-04-09 | Scorpion Therapeutics, Inc. | Compounds for use in methods of treating cancer |
| WO2025251058A1 (en) * | 2024-05-31 | 2025-12-04 | Celyn Therapeutics, Inc. | Egfr inhibitors in cancer treatment |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906194B2 (en) | 2003-10-08 | 2005-06-14 | Massachusetts Instititue Of Technology | Fluorescence assay for kinase activity |
| US7964729B2 (en) | 2006-08-28 | 2011-06-21 | Massachusetts Institute Of Technology | Sox-based kinase sensor |
| ES2570756T3 (es) * | 2009-06-15 | 2016-05-20 | Nerviano Medical Sciences Srl | Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa |
| JP5825932B2 (ja) | 2011-08-26 | 2015-12-02 | キヤノン株式会社 | 撮像装置及びその制御方法、プログラム、及び記録媒体 |
| WO2013092512A1 (en) | 2011-12-21 | 2013-06-27 | Bayer Intellectual Property Gmbh | Substituted benzylpyrazoles |
| WO2013167698A1 (en) | 2012-05-11 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| EP2976335A1 (en) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| EP2976336A1 (en) | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| CN105452237A (zh) | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| JP2016525076A (ja) | 2013-06-21 | 2016-08-22 | バイエル ファーマ アクチエンゲゼルシャフト | 置換されたベンジルピラゾール類 |
| WO2014202588A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| JP2016526540A (ja) | 2013-06-21 | 2016-09-05 | バイエル ファーマ アクチエンゲゼルシャフト | 置換ベンジルピラゾール |
| CA2928998A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| EP3143015B1 (en) | 2014-05-13 | 2019-02-20 | ARIAD Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| AR100886A1 (es) | 2014-06-17 | 2016-11-09 | Bayer Pharma AG | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas |
| AU2016212230B2 (en) * | 2015-01-28 | 2019-09-19 | Bayer Pharma Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CA2989469A1 (en) | 2015-06-17 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| US10308629B2 (en) | 2015-08-05 | 2019-06-04 | Bayer Pharma Aktiengesellschaft | 1H-pyrrol-3-amines |
| BR112018004175B8 (pt) | 2015-09-01 | 2023-10-31 | Taiho Pharmaceutical Co Ltd | Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto |
| US11339157B1 (en) * | 2017-10-24 | 2022-05-24 | Bayer Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| CA3091834A1 (en) | 2018-02-23 | 2019-08-29 | The Regents Of The University Of Michigan | Egfr dimer disruptors and use of the same |
| WO2019241715A1 (en) | 2018-06-14 | 2019-12-19 | Dana-Farber Cancer Institute, Inc. | Cyano quinoline amide compounds as her2 inhibitors and methods of use |
| WO2019246541A1 (en) | 2018-06-21 | 2019-12-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of egfr and methods of use thereof |
| CA3128946A1 (en) * | 2019-02-07 | 2020-08-13 | Bayer Aktiengesellschaft | 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors |
-
2021
- 2021-10-08 BR BR112023006531A patent/BR112023006531A2/pt unknown
- 2021-10-08 TW TW110137651A patent/TW202227063A/zh unknown
- 2021-10-08 US US18/030,211 patent/US20240101576A1/en active Pending
- 2021-10-08 KR KR1020237015734A patent/KR20230107419A/ko active Pending
- 2021-10-08 IL IL301929A patent/IL301929A/en unknown
- 2021-10-08 PH PH1/2023/500010A patent/PH12023500010A1/en unknown
- 2021-10-08 JP JP2023521702A patent/JP2023548657A/ja active Pending
- 2021-10-08 AU AU2021358596A patent/AU2021358596A1/en active Pending
- 2021-10-08 WO PCT/US2021/054191 patent/WO2022076831A2/en not_active Ceased
- 2021-10-08 CA CA3198202A patent/CA3198202A1/en active Pending
- 2021-10-08 MX MX2023004085A patent/MX2023004085A/es unknown
- 2021-10-08 EP EP21802493.3A patent/EP4225445A2/en active Pending
-
2023
- 2023-04-06 CL CL2023001012A patent/CL2023001012A1/es unknown
-
2025
- 2025-12-22 CL CL2025004052A patent/CL2025004052A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023548657A (ja) | 2023-11-20 |
| CA3198202A1 (en) | 2022-04-14 |
| MX2023004085A (es) | 2023-06-29 |
| TW202227063A (zh) | 2022-07-16 |
| KR20230107419A (ko) | 2023-07-14 |
| WO2022076831A2 (en) | 2022-04-14 |
| PH12023500010A1 (en) | 2024-03-11 |
| US20240101576A1 (en) | 2024-03-28 |
| AU2021358596A9 (en) | 2024-10-24 |
| WO2022076831A3 (en) | 2022-07-07 |
| CL2025004052A1 (es) | 2026-03-20 |
| AU2021358596A1 (en) | 2023-05-25 |
| EP4225445A2 (en) | 2023-08-16 |
| BR112023006531A2 (pt) | 2023-10-03 |
| IL301929A (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001012A1 (es) | Métodos para el tratamiento del cáncer | |
| MX2023003362A (es) | Derivados de pirrolo[3,2-c]piridin-4-ona utiles en el tratamiento del cancer. | |
| WO2020150417A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| ES2436225T3 (es) | Inhibidores TRPA1 para tratamiento del dolor | |
| JOP20220332A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| WO2022072645A3 (en) | Pyrrolopyrolidinone and pyrroloazepinone derivatives for use in treating cancer | |
| PH12021500049A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
| UA89038C2 (en) | Pyrrolotriazine compounds as kinase inhibitors | |
| WO2016210106A1 (en) | Compositions and methods for inhibiting arginase activity | |
| WO2022133046A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| MX2025015186A (es) | Inhibidores de pi3k y uso de estos | |
| MX2020002429A (es) | Compuestos para reducir la viscosidad de las formulaciones biologicas. | |
| RU2010140435A (ru) | Применение производных пиримидина для лечения egfr-зависимых заболеваний или заболеваний с приобретенной резистентностью к агентам, направленным против членов семейства egfr | |
| MX2025004532A (es) | Método para tratar el cáncer | |
| WO2005065266A3 (en) | Di-substituted pyrrolotriazine compounds | |
| RU2013148817A (ru) | Комбинации соединений-ингибиторов акт и мек и способы их применения | |
| WO2022133098A3 (en) | Compounds and compositions for treating conditions associated with sting activity | |
| WO2023107723A3 (en) | Cyclic compounds and their use for the treatment of neurological disorders | |
| WO2021164793A8 (zh) | 用作激酶抑制剂的化合物及其应用 | |
| EA200870454A1 (ru) | Способ ингибирования c-kit киназы | |
| JOP20240022A1 (ar) | مركبات وتركيبات لعلاج حالات مرتبطة بنشاط sting | |
| ATE482212T1 (de) | Pyrrolotriazinverbindungen | |
| WO2023107714A3 (en) | Heterocyclic compounds as dyrk1a inhibitors | |
| MX2021001710A (es) | Compuestos de fluoro ?-carbolina. |